Home  /  Resource Library  /  Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Results of a study show that modifying the dose of cisplatin resulted in lower levels of treatment related renal toxicity.